文献速递心力衰竭与心肌病冠心病血脂与心血管预防

利伐沙班对心衰合并冠心病窦性心律患者卒中或TIA的影响:COMMANDER HF分析

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
PubMed 文献 · Eur Heart J · 2019-01-01

COMMANDER HF事后分析纳入5022例HFrEF合并冠心病窦性心律患者,随机接受利伐沙班2.5mg每日两次或安慰剂。中位随访20.5个月,利伐沙班使卒中或TIA风险降低32%(aHR 0.68,95%CI 0.49-0.94),主要安全终点无显著差异。

要点

  • HFrEF合并CAD窦性心律患者卒中/TIA风险高,近半数致残或致死。
  • 利伐沙班2.5mg每日两次降低卒中/TIA风险32%,需治疗164例/年预防1例事件。
  • 致命出血或关键部位出血发生率与安慰剂相似。

核心结论

  • 在HFrEF合并CAD且窦性心律患者中,利伐沙班2.5mg每日两次较安慰剂显著降低卒中或TIA风险32%。
  • 主要安全终点致命出血或关键部位出血发生率两组相似。

研究设计与样本

  • COMMANDER HF为双盲随机试验,纳入5022例HFrEF(≤40%)、利钠肽升高、CAD且窦性心律患者。
  • 患者在接受抗血小板治疗基础上随机接受利伐沙班2.5mg每日两次或安慰剂。
  • 本分析为事后分析,主要神经结局为首次卒中或TIA时间。

主要发现

  • 中位随访20.5个月,共发生150例全因卒中(127例)或TIA(23例)事件。
  • 卒中事件中缺血性占82%,出血性占11%。
  • 首次卒中中47.5%为致残(16.5%)或致死(31%)。
  • 利伐沙班组卒中或TIA发生率为1.29例/100患者年,安慰剂组为1.90例/100患者年。
  • 校正后风险比0.68(95%CI 0.49-0.94),每治疗164例/年预防1例卒中或TIA。

关键数值与推荐

  • 卒中/TIA预测因素包括既往卒中、低体重指数、地理区域和CHA2DS2-VASc评分。
  • 主要安全终点致命出血或关键部位出血:利伐沙班0.44例/100患者年 vs 安慰剂0.55例/100患者年。

临床怎么用

  • 对于HFrEF合并CAD且窦性心律患者,在抗血小板治疗基础上加用利伐沙班2.5mg每日两次可降低卒中/TIA风险。
  • 需权衡缺血与出血风险,尤其关注既往卒中、低体重指数等高危患者。

局限性

  • 本分析为事后分析,结论需谨慎解读。
  • 卒中/TIA事件数量较少,统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Stroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first occurrence of death, stroke, or myocardial infarction compared with placebo in patients with HFrEF, coronary artery disease (CAD), and sinus rhythm. We now examine the incidence, timing, type, severity, and predictors of stroke or a transient ischaemic attack (TIA), and seek to establish the net clinical benefit of treatment with low-dose rivaroxaban. METHODS AND RESULTS: In this double-blind, randomized trial, 5022 patients who had HFrEF(≤40%), elevated natriuretic peptides, CAD, and who were in sinus rhythm were treated with rivaroxaban 2.5 mg b.i.d. or placebo in addition to antiplatelet therapy, after an episode of worsening HF. The primary neurological outcome for this post hoc analysis was time to first event of any stroke or TIA. Over a median follow-up of 20.5 (25th-75th percentiles 20.0-20.9) months, 150 all-cause stroke (127) or TIA (23) events occurred (ischaemic stroke in 82% and haemorrhagic stroke in 11% of stroke events). Overall, 47.5% of first-time strokes were either disabling (16.5%) or fatal (31%). Prior stroke, low body mass index, geographic region, and the CHA2DS2-VASc score were predictors of stroke/TIA. Rivaroxaban significantly reduced the primary neurological endpoint of all-cause stroke or TIA compared with placebo by 32% (1.29 events vs. 1.90 events per 100 patient-years), adjusted for the time from index HF event to randomization and stratified by geographic region (adjusted hazard ratio 0.68, 95% confidence interval 0.49-0.94), with a number needed to treat of 164 patients per year to prevent one stroke/TIA event. The principal safety endpoint of fatal bleeding or bleeding into a critical space, occurred at a similar rate on rivaroxaban and placebo (0.44 events vs. 0.55 events per 100 patient-years). CONCLUSIONS: Patients with HFrEF and CAD are at risk for stroke or TIA in the period following an episode of worsening heart failure in the absence of atrial fibrillation. Most strokes are of ischaemic origin and nearly half are either disabling or fatal. Rivaroxaban at a dose of 2.5 mg b.i.d. reduced rates of stroke or TIA compared with placebo in this population. TRIAL REGISTRATION: COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure); ClinicalTrials.gov NCT01877915.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Mehra MR, Vaduganathan M, Fu M, et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J. 2019. PMID: 31461239. doi:10.1093/eurheartj/ehz427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。